Table E3.
Characteristics of 23 individuals fully vaccinated with mRNA-1273
| Patient ID | Age (years) | Sex | Days after second dose | NT analysis | Total anti-RBD Ig (Wantai) |
Anti-S1 IgG (Euroimmun) |
Anti-S1 IgA (Euroimmun) |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Results | RoA | Results | Concentration (BAU∙mL−1) | Results | RoA | |||||
| M1 | 31 | M | 104 | Yes | Positive | 17.55 | Positive | 626.20 | Positive | 6.03 |
| M2 | 33 | F | 50 | Yes | Positive | 17.65 | Positive | 433.91 | Positive | 0.87 |
| M3 | 47 | F | 50 | Yes | Positive | 17.41 | Positive | 139.59 | Negative | 0.16 |
| M4 | 64 | M | 57 | Yes | Positive | 17.09 | Positive | 492.38 | Positive | 5.91 |
| M5 | 66 | F | 50 | Yes | Positive | 18.75 | Positive | 736.14 | Positive | 9.13 |
| M6 | 36 | M | 50 | Yes | Positive | 18.51 | Positive | 672.50 | Negative | 0.18 |
| M7 | 57 | M | 50 | Yes | Positive | 18.08 | Positive | 569.36 | Positive | 3.31 |
| M8 | 54 | M | 50 | Yes | Positive | 18.27 | Positive | 458.47 | Positive | 3.40 |
| M9 | 43 | F | 50 | Yes | Positive | 18.54 | Positive | 566.93 | Positive | 4.99 |
| M10 | 46 | F | 52 | Yes | Positive | 18.66 | Positive | 658.25 | Positive | 3.53 |
| M11 | 62 | F | 52 | Yes | Positive | 18.08 | Positive | 695.31 | Positive | 8.07 |
| M12 | 29 | M | 52 | Yes | Positive | 20.48 | Positive | 738.90 | Negative | 0.23 |
| M13 | 63 | M | 52 | Yes | Positive | 18.56 | Positive | 547.37 | Positive | 3.03 |
| M14 | 63 | F | 52 | Yes | Positive | 18.53 | Positive | 679.68 | Positive | 6.10 |
| M15 | 54 | F | 57 | Yes | Positive | 18.15 | Positive | 349.20 | Positive | 3.88 |
| M16 | 33 | F | 57 | Yes | Positive | 19.48 | Positive | 632.40 | Positive | 4.32 |
| M17 | 63 | F | 57 | Yes | Positive | 18.13 | Positive | 583.31 | Positive | 0.93 |
| M18 | 50 | M | 57 | Yes | Positive | 18.55 | Positive | 618.59 | Positive | 5.29 |
| M19 | 61 | F | 57 | No | Positive | 19.36 | Positive | 672.88 | Positive | 7.12 |
Results for total Ig against SARS-CoV-2 RBD and for IgA against SARS-CoV-2 domain S1 are shown as RoA. For IgG against SARS-CoV-2 domain, S1 results are presented in binding antibody units per milliliter of serum (BAU∙mL−1). Serum samples used for the neutralization experiments are indicated in “NT analysis” column. The average age of the participants was 51 years; the percentage of women was 58%. All samples of mRNA-1273 vaccinees were taken between 50 and 104 days after the second dose.